Pharmaceuticals 2010, 3(8), 2426-2440; doi:10.3390/ph3082426
Review

The Impact of Residual Symptoms in Major Depression

email
Received: 30 June 2010; in revised form: 2 July 2010 / Accepted: 22 July 2010 / Published: 3 August 2010
(This article belongs to the Special Issue Antidepressants)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: The current definition of remission from major depressive disorder does not fully take into account all aspects of patient recovery. Residual symptoms of depression are very common in patients who are classified as being in remission. Patients with residual symptoms are at increased risk of functional and interpersonal impairments, and are at high risk for recurrence of depression. This article discusses the incidence of residual symptoms of depression, as well as the risks and consequences of these symptoms, and will review the state of current treatment.
Keywords: major depressive disorder, MDD, antidepressive agents, residual symptoms, depression, depression treatment
PDF Full-text Download PDF Full-Text [166 KB, Updated Version, uploaded 5 August 2010 10:52 CEST]
The original version is still available [157 KB, uploaded 3 August 2010 08:28 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Israel, J.A. The Impact of Residual Symptoms in Major Depression. Pharmaceuticals 2010, 3, 2426-2440.

AMA Style

Israel JA. The Impact of Residual Symptoms in Major Depression. Pharmaceuticals. 2010; 3(8):2426-2440.

Chicago/Turabian Style

Israel, Joshua A. 2010. "The Impact of Residual Symptoms in Major Depression." Pharmaceuticals 3, no. 8: 2426-2440.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert